Overview

Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study is to determine the efficacy of Jaktinib versus Hydroxycarbamid in participants with Intermediate-2 or High-risk myelofibrosis
Phase:
Phase 3
Details
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Treatments:
Hydroxyurea